The Tragicomedy of Iovance: A Tale of Biotech’s Fickle Fortune

Once, this purveyor of cellular therapies basked in the warm glow of approval from the Food and Drug Administration (FDA). Alas, triumph proved fleeting, for no sooner had the market toasted its success than it stumbled into shadows cast by less-than-stellar developments. Let us explore why this cancer-focused minstrel has sung both ballads of glory and dirges of despair-and whether its encore might yet ascend to loftier heights.






